BeiGene looks beyond Phase III setback to build case for Brukinsa

Although a Phase III miss in Waldenström’s macroglobulinemia scuttles Brukinsa’s near-term chances to add a superiority claim to its label, BeiGene believes the Btk inhibitor's combined efficacy and safety profile differentiates it from Imbruvica.

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) dropped $10.94 to $165.09 on NASDAQ Monday after reporting Brukinsa zanubrutinib failed to show superiority to Imbruvica ibrutinib in the Phase III ASPEN study for WM patients...